会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • NOVEL TARGET GENES FOR DISEASES OF THE HEART
    • 心脏疾病的新目标基因
    • WO0192567A3
    • 2003-02-13
    • PCT/EP0106165
    • 2001-05-30
    • MEDIGENE AGBUNK DANIELAREUNER BIRGITBECK JOACHIMHENKEL THOMAS
    • BUNK DANIELAREUNER BIRGITBECK JOACHIMHENKEL THOMAS
    • A01K67/027A61K38/00A61K45/00A61K48/00A61P9/00A61P9/02A61P9/04A61P9/10A61P9/12C07K14/47C12N15/09C12N15/85C12Q1/50C12Q1/68G01N33/15G01N33/50G01N33/53G01N33/566A61K49/00C07K16/18
    • C12N15/8509A01K2217/05A01K2217/075A01K2267/03A01K2267/0375C07K14/47C12Q1/6883C12Q2600/136C12Q2600/158
    • The present invention relates to a variety of genes abnormally expressed in heart tissue as well as to fragments of such genes. Assessment of the expression level of these genes may be used for testing the predisposition of mammals and preferably humans for a heart disease or for an acute state of such a disease. Preferred diseases in accordance with the invention are congestive heart failure, dilative cardiomyopathy, hypertrophic cardiomyopathy and ischemic cardiomyopathy. The present invention further relates to methods of identifying compounds capable of normalizing the expression level of the aforementioned genes and of further genes affected by the abnormal expression. The identified compounds may be used for formulating compositions, preferably pharmaceutical compositions for preventing or treating diseases. They may also be used as lead compounds for the development of medicaments having an improved efficiency, a longer half-life, a decreased toxicity etc. and to be employed in the treatment of heart diseases. Included in the invention are also somatic gene therapy methods comprising the introduction of at least one functional copy of any of the above-mentioned genes into a suitable cell. Finally, the invention relates to non-human transgenic animals comprising at least one of the aforementioned genes in their germ line. The transgenic animals of the invention may be used for the development of medicaments for the treatment of heart diseases.
    • 本发明涉及在心脏组织中异常表达的各种基因以及这些基因的片段。 这些基因的表达水平的评估可以用于测试哺乳动物和优选人心脏病或这种疾病的急性状态的倾向。 根据本发明的优选疾病是充血性心力衰竭,扩张性心肌病,肥厚性心肌病和缺血性心肌病。 本发明还涉及鉴定能够使上述基因的表达水平正常化的化合物和受异常表达影响的其它基因的方法。 鉴定的化合物可用于配制组合物,优选用于预防或治疗疾病的药物组合物。 它们也可以用作开发具有改善的效率,更长的半衰期,降低的毒性等等并且用于治疗心脏病的药物的铅化合物。 本发明还包括体细胞基因治疗方法,其包括将任何上述基因的至少一个功能拷贝引入合适的细胞中。 最后,本发明涉及在其种系中包含至少一个上述基因的非人转基因动物。 本发明的转基因动物可用于开发用于治疗心脏病的药物。
    • 5. 发明申请
    • NOVEL TARGET GENES FOR DISEASES OF THE HEART
    • 心脏疾病的新目标基因
    • WO03006687A3
    • 2003-08-28
    • PCT/EP0207704
    • 2002-07-10
    • MEDIGENE AGREUNER BIRGITBUNK DANIELAHENKEL THOMAS
    • REUNER BIRGITBUNK DANIELAHENKEL THOMAS
    • C12Q1/68
    • C12Q1/6883C12Q2600/158
    • The present invention relates to a variety of genes abnormally expressed in heart tissue as well as to fragments of such genes. Assessment of the expression level of these genes may be used for testing the predisposition of mammals and preferably humans of a heart disease or for an acute state of such a disease. Preferred diseases in accordance with the invention are congestive heart failure, dilative cardiomyopathy, hypertrophic cardiomyopathy and ischemic cardiomyopathy. The present invention further relates to methods of identifying compounds capable of normalizing the expression level of the aforementioned genes and of further genes affected by the abnormal expression. The identified compounds may be used for formulating compositions, preferably pharmaceutical compositions for preventing or treating diseases. They may be used as lead compounds for the development of medicament having an inproved efficiency, a longer half-life, a decreased toxicity etc. and to be employed in the treatment of heart diseases. Included in the invention are also somatic gene therapy methods comparing the introduction of at least one functional copy of any of the above-mentioned genes into a suitable cell. Finally, the invention relates to non-human transgenic animals comprising at least one of the aformentioned genes in their germ line. The transgenic animals of the invention may be used for the development of medicaments for the treatment of heart diseases.
    • 本发明涉及在心脏组织中异常表达的各种基因以及这些基因的片段。 这些基因的表达水平的评估可以用于测试哺乳动物,优选人心脏病或这种疾病的急性状态的倾向。 根据本发明的优选疾病是充血性心力衰竭,扩张性心肌病,肥厚性心肌病和缺血性心肌病。 本发明还涉及鉴定能够使上述基因的表达水平正常化的化合物和受异常表达影响的其它基因的方法。 鉴定的化合物可用于配制组合物,优选用于预防或治疗疾病的药物组合物。 它们可以用作开发具有提高的效率,更长的半衰期,降低的毒性等等并用于治疗心脏病的药物的铅化合物。 本发明中还包括体细胞基因治疗方法,比较将任何上述基因的至少一个功能拷贝引入合适的细胞中。 最后,本发明涉及在其种系中包含至少一个上述基因的非人转基因动物。 本发明的转基因动物可用于开发用于治疗心脏病的药物。
    • 7. 发明申请
    • METHOD FOR SECURELY TRANSMITTING PROTECTED DATA
    • 方法数据安全传输而得到保护
    • WO0072544A3
    • 2001-09-07
    • PCT/EP0004351
    • 2000-05-15
    • SMARTRING GMBH GES FUER SICHERREIF HOLGERHENKEL THOMAS
    • REIF HOLGERHENKEL THOMAS
    • H04L29/06H04W88/02G07F7/10H04Q7/38
    • H04W12/10H04L63/0442H04L63/0853H04L63/12H04W88/02
    • The invention relates to a method for the secure transmission of protected data from a first terminal (1) within a first security area (6) to a second terminal (2) within a second security area (10), which is different from the first security area. The inventive method comprises the following steps: providing useful data in the first terminal; generating the protected data in the first terminal by adding first security characteristics (8a) to the useful data; transmitting the protected data within the first security area to an area transformer (9), by a first communications connection (4), said area transformer being integrated into both the first and the second security areas; transforming at least some of the first security characteristics into second security characteristics (11a) by means of the area transformer; transmitting the protected data within the second security area to a second terminal, by a second communications connection (7). The protected data can then be converted back into useful data in said second terminal.
    • 本发明涉及一种用于从一个第一安全区(6)的第二终端(2)内的第一终端(1)的第二安全区域(10)内的保护的数据的安全传输的方法,其是从所述第一安全区域不同。 该方法包括以下步骤:在第一终端的用户数据的提供; 生成通过加入第一安全特征(8a)的用户数据中的第一终端的受保护的数据; 经由第一通信链路(4)连接到域变换器(9),其集成在所述第一以及到第二安全域的第一安全区域内的受保护数据的传输; 将至少一些所述第一单元安全特性到第二安全功能(11A)由域变换器的; 通过第二通信链路(7)至所述第二终端,其中所述受保护的数据可以被转换回有效载荷中的第二安全区域内的受保护数据的传输。